Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,273 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 10,402 · Balance 58,273 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 20:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 10,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279541 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,273 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:13 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 14,164 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-004071 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,871 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026. Read SEC document |
| July 09, 2024 Filed Jul 11, 2024 20:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 5,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-003909 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,707 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-003961 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,936 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2024 annual meeting of the Company's stockholders or June 14, 2024. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 7,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-004301 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,436 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2023 annual meeting of the Company's stockholders or June 8, 2023. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004429 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,482 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on the earlier of the 2022 annual meeting of the Company's stockholders or June 16, 2022. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 22:14 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 9,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-006337 · ownership.xml · nonDerivative · entry 1 Richard Stephen · CIK 0001823843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,310 F1 · security: These shares represent restricted stock units. Each restricted stock unit represents the contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in three equal annual installments immediately prior to the Anika Therapeutics, Inc., Annual Meetings of Stockholders in 2021, 2022, and 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.